Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Seizures × Solutions × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Keratosis, Actinic 4 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors Harboring NTRK Fusion 1 Small Cell Lung Carcinoma 1 Seizures 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Lymphoma, T-Cell 1 Lung Neoplasms 1 Leukemia 1 Lennox Gastaut Syndrome 1 Head and Neck Neoplasms 1 Epilepsies, Myoclonic 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Anemia 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1

Interventions

Cannabidiol 3 enzalutamide 1 Solutions 1 Lenalidomide 1 Everolimus 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05485831 2026-02-17

EpiTALY

Jazz Pharmaceuticals

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡